

**REMARKS**

Applicants respectfully request that the foregoing amendments be made prior to examination of the present application. The amendments are made to direct insertion of the required references to SEQ ID NOs. into the specification.

Respectfully submitted,

Date: May 28, 2003

FOLEY & LARDNER  
Customer Number: 22428



**22428**

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5407  
Facsimile: (202) 672-5399

By Michele M. Simkin

Michele M. Simkin  
Attorney for Applicants  
Registration No. 34,717

**MARKED UP VERSION SHOWING CHANGES MADE**

**IN THE SPECIFICATION:**

Please replace paragraph number 0023 with the following paragraph:

Figure 8 is a bar graph of the results of screening of a (SEQ ID NO: 2) GSTA library.

Please replace paragraph number 0044 with the following paragraph:

In a preferred embodiment, the peptides derived from a cancer-associated mucin, and is in particular a MUC1 core protein. The MUC1 tandem repeat derived sequence (SEQ ID NO: 1) GVTSAPDTRPAPGSTA, contains five O-glycosylation sites, two serines and three threonines, and is an example of a peptide that can be glycosylated according to the present invention to create a glycopeptide library. If all possible glycosylation sites in a tandem repeat are used only once in primary glycosylation with N-acetylgalactosamine (Tn antigen), five different monoglycosylated tandem repeats result, but if glycosylation is randomized between 0 and 5 sites, there are 32 different combinations of glycosylated tandem repeats. If 0 to 5 sialic acids are then randomly added at the 6-position of the existing N-acetylgalactosamines, the possible number of glycoforms increases to 243. These will carry only combinations and varied numbers of Tn and STn. If another donor is added at each glycosylation, *e.g.*, TF along with the first and GlcNAc along with the second, a total of 16807 glycosylation variants of MUC1 tandem repeat will be produced. This library will constitute more than 90% of all truncated versions (core structures) that may be associated with cancerous MUC1 mucin. These are useful as vaccine components.

Please replace paragraph number 0046 with the following paragraph:

The library of (SEQ ID NO: 2) GSTA glycopeptides modelled on naturally-existing mucins, is small enough that the components can be characterized by mass

spectrometry. It is therefore very useful in gaining a precise understanding of glycosylation patterns of the MUC1 core protein, which is necessary in order to design effective therapeutic vaccines and diagnostic tools.

Please replace paragraph number 0048 with the following paragraph:

GSTA (SEQ ID NO: 2) is a four amino acid residue of MUC1, which has two unique sites for glycosylation, the serine residue (S) and the threonine residue (T). It is manually synthesized in solution with N-terminal Fmoc and C-terminal benzyl, with serine and threonine hydroxyls free.

**IN THE CLAIMS:**

3. (Amended) A method according to claim 2, wherein said peptide has an amino acid sequence (SEQ ID NO: 1) GVT SAPDTRPAPGSTA.

4. (Amended) A method according to claim 2, wherein said peptide has an amino acid sequence (SEQ ID NO: 2) GSTA.